Mölnlycke and Ondine join forces against HAIs

On September 23, 2024, Mölndal, Sweden-based Mölndycke Health Care announced a partnership with Ondine to distribute Steriwave, a technology aimed at combating healthcare-associated infections (HAIs) and antimicrobial resistance (AMR). This collaboration is particularly significant as it leverages Mölndycke's extensive distribution networks across over 100 countries, with an initial focus on the UK market, where Steriwave is already in use at several NHS Trusts. The introduction of Steriwave is timely, as HAIs pose a substantial challenge to healthcare systems, consuming a significant portion of public sector budgets and leading to avoidable deaths. The UK government is actively working to reduce post-surgical infections, which often require prolonged antibiotic treatments, as part of its five-year action plan for AMR. Steriwave's effectiveness lies in its ability to rapidly decolonize pathogens without contributing to resistance, making it a viable alternative to traditional antibiotics. Hospitals that have implemented Steriwave report high compliance rates among both staff and patients, indicating its potential for widespread adoption. Mölndycke plans to incorporate Steriwave into its infection control portfolio, enhancing its offerings to healthcare providers. The distribution of Steriwave is set to begin in the UK in the fourth quarter of 2024, with plans for expansion into the EU and Middle East in 2025, ultimately aiming to broaden the impact of this innovative technology on a global scale.